Treatment of diabetes with copper binding compounds

• US 7,459,446 B2
• Filed: 12/28/2004
• Issued: 12/02/2008
• Est. Priority Date: 09/25/1998
• Status: Expired due to Term

• Current Assignee: Philera New Zealand Limited
• Original Assignee: Protemix Corporation Limited
• Inventors: Baker, John Richard, Cooper, Garth J. S.
• Primary Examiner(s): Henley, III; Raymond J
• Application Number:
  US11/023,827
• Publication Number:
  US 20050159489A1
• Time in Patent Office: 1,435 Days
• Field of Search: 514/183, 514/400, 514/561, 514/562, 514/674
• US Class Current: 514/183
• CPC Class Codes: A61K 31/132 having two or more amino groups, e.g. spermidine, putrescine
• CPC Class Codes: A61K 31/15 Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00

Abstract

Novel methods of treating a patient for diseases, disorders, and conditions including diabetes mellitus, comprising administering, for example, copper binding compounds.

Claims

1. A method of treating a human for diabetes, the method comprising administering to said human a composition comprising a therapeutically effective amount of a pharmaceutically acceptable cupric binding agent selected from the group consisting of triethylenetetramine dihydrochloride, penicillamine, sar, diamsar, and o-phenanthroline.

2. The method of claim 1 wherein said human has type 1 diabetes.

3. The method of claim 1 wherein said human has type 2 diabetes.

4. The method of any of claims 1, 2 or 3, wherein said cupric binding agent is a copper chelator.

5. The method of claim 4, wherein said copper chelator is administered orally.

7. The method of claim 1 wherein said human has type 1 diabetes.

8. The method of claim 1 wherein said human has type 2 diabetes.

6. A method of treating a human for diabetes, the method comprising administering to said human a composition comprising a therapeutically effective amount of a pharmaceutically acceptable oxidized copper binding agent.

9. The method of any of claims 6, 7, or 8, wherein said copper binding agent is a copper chelator.

10. The method of claim 9, wherein said copper chelator is administered orally.

11. A method of treating one or more long-term complications of diabetes in a human suffering therefrom, the method comprising administering a composition consisting essentially of a cupric binding agent in an amount effective to ameliorate one or more of said conditions.

12. The method of claim 11 wherein said human has type 1 diabetes.

13. The method of claim 11 wherein said human has type 2 diabetes.

14. The method of any of claims 11, 12 or 13, wherein said cupric binding agent is a copper chelator.

15. The method of claim 14, wherein said copper chelator is administered orally.

16. A method for minimizing or reducing tissue damage associated with diabetes mellitus in a human, which comprises the prophylactic administration to a human of a therapeutically effective amount of a cupric binding agent.

17. The method of claim 16 wherein said human has type 1 diabetes.

18. The method of claim 16 wherein said human has type 2 diabetes.

19. The method of any of claims 16, 17 or 18, wherein said cupric binding agent is a copper chelator.

20. The method of claim 19, wherein said copper chelator is administered orally.

21. A method of treating one or more long-term complications of diabetes in a human suffering therefrom, the method comprising administering a composition consisting essentially of a compound that can bind or chelate oxidized, copper in an amount effective to ameliorate one or more of said conditions.

22. The method of claim 21 wherein said human has type 1 diabetes.

23. The method of claim 21 wherein said human has type 2 diabetes.

24. The method of any of claims 21, 22, or 23, wherein said compound is a copper chelator.

25. The method of claim 21, wherein said copper chelator is administered orally.

26. A method for minimizing or reducing tissue damage associated with diabetes mellitus in a human, which comprises the prophylactic administration to a human of a therapeutically effective amount of a compound that can bind or chelate oxidized copper.

27. The method of claim 26 wherein said human has type 1 diabetes.

28. The method of claim 26 wherein said human has type 2 diabetes.

29. The method of any of claims 26, 27, 28, wherein said compound is a copper chelator.

30. The method of claim 29, wherein said copper chelator is administered orally.

31. A method of treating one or more long-term complications of diabetes in a human suffering therefrom, the method comprising forming a cupric complex within the human by administering a composition consisting essentially of an effective amount of a copper binding agent.

32. The method of claim 31 wherein said human has type 1 diabetes.

33. The method of claim 31 wherein said human has type 2 diabetes.

34. The method of any of claims 31, 32, or 33, wherein said copper binding agent is a copper chelator.

35. The method according to claim 34 wherein said copper chelator is administered orally.

40. The method according to claim 34 wherein said copper chelator is administered orally.

36. A method of treating one or more long-term complications of diabetes in a human suffering therefrom, the method comprising forming an oxidized copper complex within the human by administering a composition consisting essentially of an effective amount of a copper binding agent.

37. The method of claim 36 wherein said human has type 1 diabetes.

38. The method of claim 36 wherein said human has type 2 diabetes.

39. The method of any of claims 36, 37, or 38, wherein said copper binding agent is a copper chelator.

41. A method for minimizing or reducing tissue damage associated with diabetes mellitus in a human, the method comprising forming a cupric complex within the human by prophylactically administering an effective amount of a copper binding agent.

42. The method of claim 41 wherein said human has type 1 diabetes.

43. The method of claim 41 wherein said human has type 2 diabetes.

44. The method of any of claims 41, 42, or 43, wherein said copper binding agent is a copper chelator.

45. The method according to claim 44 wherein said copper chelator is administered orally.

46. A method for minimizing or reducing tissue damage associated with diabetes mellitus in a human, the method comprising forming an oxidized copper complex within the human by prophylactically administering an effective amount of a copper binding agent.

47. The method of claim 46 wherein said human has type 1 diabetes.

48. The method of claim 46 wherein said human has type 2 diabetes.

49. The method of any of claims 46, 47, or 48, wherein said copper binding agent is a copper chelator.

50. The method according to claim 49 wherein said copper chelator is administered orally.